NASDAQ:STMLStemline Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Stemline Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.15 +0.21 (+1.76 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$11.90Now: $12.15▼$12.1750-Day Range$4.75MA: $9.10▼$12.2252-Week Range$3.21Now: $12.15▼$18.22Volume1.37 million shsAverage Volume1.39 million shsMarket Capitalization$638.01 millionP/E RatioN/ADividend YieldN/ABeta1.78 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 2.2 Analyst's Opinion Consensus RatingStemline Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.31, Stemline Therapeutics has a potential downside of 6.9% from its current price of $12.15.Amount of Analyst CoverageStemline Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.2 Community Rank Outperform VotesStemline Therapeutics has received 445 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStemline Therapeutics has received 254 “underperform” votes. (Add your “underperform” vote.)Community SentimentStemline Therapeutics has received 63.66% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote “Outperform” if you believe STML will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStemline Therapeutics does not currently pay a dividend.Dividend GrowthStemline Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stemline Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $517,447.00 in company stock.Percentage Held by InsidersOnly 11.20% of the stock of Stemline Therapeutics is held by insiders.Percentage Held by Institutions75.80% of the stock of Stemline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stemline Therapeutics are expected to grow in the coming year, from ($1.29) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stemline Therapeutics is -7.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stemline Therapeutics is -7.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStemline Therapeutics has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.2Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STML Previous Symbol CUSIPN/A CIK1264587 Webwww.stemline.com Phone646-502-2311Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$43.22 million Price / Sales14.76 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book3.73Profitability EPS (Most Recent Fiscal Year)($1.83) Net Income$-76,820,000.00 Net Margins-150.30% Return on Equity-48.14% Return on Assets-41.35%Miscellaneous Employees92 Outstanding Shares52,511,000Market Cap$638.01 million Next Earnings Date8/7/2020 (Estimated) OptionableOptionable NASDAQ:STML Rates by TradingView Receive STML News and Ratings via Email Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter. Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions How has Stemline Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Stemline Therapeutics' stock was trading at $4.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STML shares have increased by 159.1% and is now trading at $12.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Stemline Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Stemline Therapeutics. When is Stemline Therapeutics' next earnings date? Stemline Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Stemline Therapeutics. How were Stemline Therapeutics' earnings last quarter? Stemline Therapeutics Inc (NASDAQ:STML) issued its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.09. Stemline Therapeutics had a negative net margin of 150.30% and a negative return on equity of 48.14%. View Stemline Therapeutics' earnings history. What price target have analysts set for STML? 8 equities research analysts have issued 12 month price objectives for Stemline Therapeutics' stock. Their forecasts range from $8.00 to $12.50. On average, they expect Stemline Therapeutics' share price to reach $11.31 in the next year. This suggests that the stock has a possible downside of 6.9%. View analysts' price targets for Stemline Therapeutics. Has Stemline Therapeutics been receiving favorable news coverage? News coverage about STML stock has trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutStemline Therapeutics. Who are some of Stemline Therapeutics' key competitors? Some companies that are related to Stemline Therapeutics include Intercept Pharmaceuticals (ICPT), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX), Principia Biopharma (PRNB), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Ligand Pharmaceuticals (LGND), Passage Bio (ZNTL) and Epizyme (EPZM). View all competitors. What other stocks do shareholders of Stemline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Gilead Sciences (GILD), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE). Who are Stemline Therapeutics' key executives? Stemline Therapeutics' management team includes the following people: Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)Mr. Robert Francomano, Sr. VP & Global Head of CommercialMr. John A. Salvagno, Sr. VP of Quality & Operations What is Stemline Therapeutics' stock symbol? Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML." Who are Stemline Therapeutics' major shareholders? Stemline Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.42%), The Manufacturers Life Insurance Company (4.93%), State Street Corp (4.20%), Empire Life Investments Inc. (1.87%), Stonepine Capital Management LLC (1.69%) and Geode Capital Management LLC (1.30%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein, Kenneth Hoberman and Robert Francomano. View institutional ownership trends for Stemline Therapeutics. Which institutional investors are selling Stemline Therapeutics stock? STML stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Rhenman & Partners Asset Management AB, Morgan Stanley, UBS Group AG, Telemetry Investments L.L.C., Victory Capital Management Inc., Victory Capital Management Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein, Kenneth Hoberman, and Robert Francomano. View insider buying and selling activity for Stemline Therapeutics. Which institutional investors are buying Stemline Therapeutics stock? STML stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Empire Life Investments Inc., Cambiar Investors LLC, Bullseye Asset Management LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Los Angeles Capital Management & Equity Research Inc., and Weiss Multi Strategy Advisers LLC. View insider buying and selling activity for Stemline Therapeutics. How do I buy shares of Stemline Therapeutics? Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Stemline Therapeutics' stock price today? One share of STML stock can currently be purchased for approximately $12.15. How big of a company is Stemline Therapeutics? Stemline Therapeutics has a market capitalization of $638.01 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76,820,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe. What is Stemline Therapeutics' official website? The official website for Stemline Therapeutics is www.stemline.com. How can I contact Stemline Therapeutics? Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
